The Health Justice Initiative in South Africa has reported that the South African government is utilizing the Competition Act to investigate a complaint against Otsuka. The HJI has reported that the company is alleged to be engaging in exclusionary practices for the drug Delamanid. A hearing for the complaint has not been scheduled with the tribunal at this time.
top of page
Recent Posts
See AllPhumeza Tisile was treated for MDR-TB in 2010 and suffered severe side effects from the drug, kanamycin. Her experiences drove her to...
10
The WHO has released new guidelines for prophylactic TB treatments. Among the updates to the guidelines are adjusted dosage...
20
The TB-CAPT consortium released a new study recently that showed that the new Xpert MTB/XDR testing can provide signigificantly faster...
100
bottom of page
Comments